

Special Issue

Pharmacology and Toxicology of Metal-Based Therapeutics

Message from the Guest Editor

Many metals are essential for maintaining proper body functions through a number of biological processes. Hence, imbalanced metal homeostasis either by deficiency or by overload of metals is associated with organ dysfunction that leads to various disorders. In contrast, non-essential metals can exert toxic effects even at low levels. However, the precise mechanisms of metal toxicity are not clear. Interestingly, there has been rapid progress in disease detection and therapy using novel metal-based drugs and technologies, but their efficacy and safety remain to be fully understood and clarified. This Special Issue aims to include original research and review articles on the pharmacology and toxicology of metals or metal-based diagnostics and therapeutics. Examples are studies focusing on the current advances in beneficial or toxic effects of metal nutrients (e.g., iron, zinc, copper, manganese), heavy metals (single or mixtures), drugs that modulate metal transport and status (e.g., metal absorption enhancers, metal chelators) or metal-associated materials (e.g., metal nanoparticles).

Guest Editor

Dr. Jonghan Kim

Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA, USA

Deadline for manuscript submissions

closed (31 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/114091

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).